Changeflow GovPing Healthcare & Life Sciences Observational Study of Lymphocyte Subpopulation...
Routine Notice Added Final

Observational Study of Lymphocyte Subpopulations in PGCG, 28 Patients

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

ClinicalTrials.gov registration NCT07551310 describes an observational study evaluating lymphocyte subpopulations in Peripheral Giant Cell Granuloma tissues versus adjacent healthy gingival tissues. The study enrolled 28 systemically healthy, non-smoking patients diagnosed with PGCG. Biopsy samples were collected during surgical excision and analyzed via immunohistochemistry for CD3, CD4, CD8, CD20, and CD79a markers.

“A total of 28 systemically healthy, non-smoking patients diagnosed with PGCG are included in this study.”

NIH , verbatim from source
Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.

What changed

This ClinicalTrials.gov study registration documents a prospective observational investigation of immune cell markers in Peripheral Giant Cell Granuloma (PGCG), a non-neoplastic inflammatory gingival lesion. The study enrolled 28 patients who underwent surgical excision, with matched samples of diseased and healthy tissue analyzed for five lymphocyte subpopulation markers.

For clinical research sites and oral pathology investigators, this study adds to the evidence base on the immunological characteristics of PGCG. The methodological approach—using immunohistochemistry to compare diseased and healthy tissue from the same patients—may inform future study design for similar gingival lesion research.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Lymphocyte Subpopulations in Peripheral Giant Cell Granuloma

Observational NCT07551310 Kind: OBSERVATIONAL Apr 24, 2026

Abstract

Peripheral giant cell granuloma (PGCG) is a non-neoplastic inflammatory lesion of gingival tissues. This study aims to evaluate and compare lymphocyte subpopulations in PGCG tissues and adjacent healthy gingival tissues obtained from the same individuals.

A total of 28 systemically healthy, non-smoking patients diagnosed with PGCG are included in this study. Biopsy samples are collected during surgical excision of PGCG lesions, and corresponding healthy gingival tissues are obtained from the same patients.

Immunohistochemical analysis is performed to assess lymphocyte subpopulations, including CD3, CD4, CD8, CD20, and CD79a. The proportions of these cells are compared between diseased and healthy tissues.

Conditions: Peripheral Giant Cell Granuloma, Gingival Lesions, Gingival Enlargement

Interventions: Immunohistochemical Analysis

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 24th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical research Immunohistochemistry Oral pathology
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Public Health Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!